Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Prochlorperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 8/20 | 0.84 |
| ▸ | LMNA | P02545 | 8/20 | 0.84 |
| ▸ | MAPT | P10636 | 7/20 | 0.84 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.84 |
| ▸ | ADRA2A | P08913 | 6/20 | 0.84 |
| ▸ | ADRA2C | P18825 | 6/20 | 0.84 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.84 |
| ▸ | HTR2A | P28223 | 6/20 | 0.84 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.84 |
| ▸ | HRH1 | P35367 | 6/20 | 0.84 |
| ▸ | DRD3 | P35462 | 6/20 | 0.84 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.84 |
| ▸ | TP53 | P04637 | 5/20 | 0.84 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.84 |
| ▸ | HTR1A | P08908 | 5/20 | 0.84 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.84 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.84 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.84 |
| ▸ | ADRA2B | P18089 | 5/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prochlorperazine SCHEMBL15511012 | 0.93 | MAPT (0.89) | LMNADRD2MAPTMAPK1CYP3A4 | |
| Prochlorperazine SCHEMBL1527298 | 0.93 | MAPT (0.89) | LMNADRD2MAPTMAPK1CYP3A4 | |
| Prochlorperazine SCHEMBL10891828 | 0.92 | MAPT (0.90) | LMNADRD2MAPTMAPK1CYP3A4 | |
| Prochlorperazine SCHEMBL18429 | 0.92 | DRD2 (1.00) | LMNADRD2MAPTMAPK1CYP3A4 | |
| Prochlorperazine SCHEMBL29358207 | 0.92 | DRD2 (1.00) | LMNADRD2MAPTMAPK1CYP3A4 | |
| Prochlorperazine SCHEMBL14126977 | 0.92 | DRD2 (1.00) | LMNADRD2MAPTMAPK1CYP3A4 | |
| Prochlorperazine SCHEMBL29369439 | 0.92 | DRD2 (1.00) | LMNADRD2MAPTMAPK1CYP3A4 | |
| Prochlorperazine SCHEMBL29089279 | 0.91 | MAPT (0.89) | LMNADRD2MAPTMAPK1CYP3A4 | |
| Prochlorperazine SCHEMBL2506559 | 0.90 | DRD2 (0.98) | LMNADRD2MAPTMAPK1CYP3A4 | |
| Prochlorperazine SCHEMBL1041250 | 0.90 | DRD2 (0.98) | LMNADRD2MAPTMAPK1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 700 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260090966-A1 | UROLITHIN COMPOSITIONS | AMAZENTIS SA (CH) | 2026-04-02 | — | — | US | claimed |
| CN-114931633-A | Preparation method and application of autoimmune disease vaccine derived from pre-activated antigen presenting cells | 苏州尔生生物医药有限公司 | 2022-08-23 | — | — | CN | claimed |
| EP-3058559-B1 | METHOD AND APPARATUS FOR ASSESSING TREATMENT EFFECTIVENESS OF TOOTH SENSITIVITY WITH ORAL CARE PRODUCT | PROCTER & GAMBLE (US) | 2018-08-29 | — | — | EP | claimed |
| EP-3058559-A1 | METHOD AND APPARATUS FOR ASSESSING TREATMENT EFFECTIVENESS OF TOOTH SENSITIVITY WITH ORAL CARE PRODUCT | The Procter & Gamble Company (US) | 2016-08-24 | — | — | EP | claimed |
| WO-2016112495-A1 | METHOD AND APPARATUS FOR ASSESSING TREATMENT EFFECTIVENESS OF TOOTH SENSITIVITY WITH ORAL CARE PRODUCT | THE PROCTER & GAMBLE COMPANY (US) | 2016-07-21 | — | — | WO | claimed |
| US-20160202137-A1 | Method and Apparatus for Assessing Treatment Effectiveness of Tooth Sensitivity with an Oral Care Product | THE PROCTER & GAMBLE COMPANY | 2016-07-14 | — | — | US | claimed |
| CN-102406640-A | Analgesic and antiphlogistic medicines and micro-needle transdermal administration method for same | SHANGHAI TAIYIN BIOLOG TECHNOLOGY CO LTD | 2012-04-11 | — | — | CN | claimed |
| US-20110151001-A1 | PHARMACEUTICAL COMPOSITION FOR EXTERNAL APPLICATION CONTAINING PROCHLORPERAZINE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2011-06-23 | — | — | US | claimed |
| EP-2298313-A1 | PHARMACEUTICAL COMPOSITION FOR EXTERNAL APPLICATION CONTAINING PROCHLORPERAZINE | Nippon Zoki Pharmaceutical Co., Ltd. (JP) | 2011-03-23 | — | — | EP | claimed |
| CN-1913900-B | Amino-substituted diaryl [ a, d ] cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric diseases | ACADIA PHARM INC | 2010-11-24 | — | — | CN | claimed |
| CN-1460476-A | Apomorphine sublingual dripping pill preparation with adjustable medicine-releasing rate | HU XIUAI (CN) | 2003-12-10 | — | — | CN | claimed |
| CN-1450883-A | Transdermal delivery system for alkaloids of aconitum species | XEL HERBACEUTICALS (US) | 2003-10-22 | — | — | CN | claimed |
| CN-1375292-A | Mixed snuff prepn. for reducing side effect of Apomorphinum | ZHEJIANG UNIV ACADEMY OF MEDIC (CN) | 2002-10-23 | — | — | CN | claimed |
| CN-1370524-A | Lovamin and its prepn process | HUARUI PHARMACEUTICAL CO LTD (CN) | 2002-09-25 | — | — | CN | claimed |
| CN-1355698-A | Compound for medicine for treating function of bronchial contraction | RESPIRATORIUS AB (SE) | 2002-06-26 | — | — | CN | claimed |
| CN-1313762-A | Apomorphine-containing dosage forms for ameliorating male erectile dysfunction | PENTECH PHARMACEUTICALS INC (US) | 2001-09-19 | — | — | CN | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| CN-1251526-A | New therapeutic combinations of mirtazapine and antipsychotic agents, for treatment of prophylaxis of psychotic disorders | AKZO NOBEL NV (NL) | 2000-04-26 | — | — | CN | claimed |
| CN-1238690-A | Improved pharmaceutical compositions | UPJOHN CO (US) | 1999-12-15 | — | — | CN | claimed |
| CN-1164189-A | Parenteral pharmaceutical compositions containing GF 120918A | GLAXO WELLCOME INC (US) | 1997-11-05 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260090966-A1 | UROLITHIN COMPOSITIONS | UTS2R, TAS2R30, TAS2R42 | DRD2 4029/4885LMNA 3052/4885MAPT 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.